Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Torokbalint – page 60

1 123 clinical trials in Torokbalint, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Torokbalint at a glance
1 123
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 123 trials in Torokbalint

Open in trial search

Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Crohn's disease

Not recruiting

Study on Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Sjogren's syndrome

Not recruiting

Study on the Effects of Abiprubart for Patients with Sjögren’s Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:KPL-404
  • Sponsor:Kiniksa Pharmaceuticals GmbH

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Astrazeneca AB

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Torokbalint

What the registry says about research in the country

01 Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating innovative combination therapies and immunotherapy approaches.

  • Advanced NSCLC Treatments
  • Stage III-IV Cancer Therapies
  • Immunotherapy Combinations

Multiple studies investigating targeted therapies for various stages of lung cancer, particularly focusing on patients with specific genetic markers and PD-L1 expression levels.

02 Respiratory Conditions

Research initiatives addressing chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), testing new therapeutic approaches.

  • Uncontrolled Asthma Management
  • COPD Treatment Optimization
  • Cystic Fibrosis Therapies

Studies evaluating novel medications and combination therapies to improve patient outcomes in chronic respiratory conditions.

03 Innovative Therapeutics

Cutting-edge research examining novel drug combinations and treatment approaches, including targeted therapies and immunotherapy agents.

  • Combination Immunotherapies
  • Targeted Molecular Therapies
  • Maintenance Treatment Strategies

Focus on developing personalized treatment approaches based on specific biomarkers and genetic profiles.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.